Willingness to pay for a hypothetical malaria vaccine in Brazil: a cross-sectional study and the implications
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: Malaria is an infection caused by protozoa of genus Plasmodium, considered the one associated with increasingly large outbreaks. Methods: A cross-sectional study was conducted with residents in the northern region of Brazil on the willingness to pay (WTP) for a hypothetical vaccine against malaria (effective protection of 80%). Results: Of 616 people interviewed, most interviewees were female (61%) and were employed (97%). The median individual maximum WTP for a hypothetical malaria vaccine was US$11.90 (BRL 50). Conclusion: The northern region of Brazil is one of the largest markets for a malaria vaccine due to its epidemiological relevance. Consequently, economic studies will be important to assist in the assessment of the potential price and value of new vaccines.
Supplementary Material
File (supplementary materials.pdf)
- Download
- 89.56 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Mace KE, Arguin PM, Tan KR. Malaria surveillance – United States. MMWR Surveil. Summ. 67(7), 1–28 (2018).
• Important to complement our knowledge of malaria.
2.
Brasil. Ministério da Saúde. Malária: o que é, causas, sintomas, tratamento, diagnóstico e prevenção (2013). http://saude.gov.br/saude-de-a-z/malaria
3.
Schindler T, Robaina T, Sax J et al. Molecular monitoring of the diversity of human pathogenic malaria species in blood donations on Bioko Island, Equatorial Guinea. Malar. J. 18(1), 9 (2019).
4.
Fundação Osvaldo Cruz. Malária (2013). https://agencia.fiocruz.br/malária
• Important to complement our knowledge of malaria.
5.
World Health Organization. Management of severe malaria (2012). https://apps.who.int/iris/bitstream/handle/10665/79317/9789241548526_eng.pdf?sequence=1
6.
Organização Pan Americana da Saúde. Folha Informativa Malária (2019). https://www.paho.org/bra/index.php?option=com_content&view=article&id=5682:folha-informativa-malaria&Itemid=812
• Important to complement our knowledge of malaria.
7.
Brasil. Agência Brasil: brasil reduz 38% casos de malária em relação a 2018 (2019). https://www.saude.gov.br/noticias/agencia-saude/45391-brasil-reduz-em-38-casos-de malaria-em-relacao-a-2018
8.
Brasil. Brasil reduz em 38% casos de malária em relação a 2018 (2019). https://www.gov.br/pt-br/noticias/saude-e-vigilancia-sanitaria/2019/04/brasil-reduz-em-38-casos-de-malaria-em-relacao-a-2018
9.
Parente AT. Incidence of Malaria in the State of Pará and its relationship with regional climatic variability. Masters dissertation. 99 (2007).
10.
Brasil. Guia de tratamento da malária no Brasil (2020). https://portalarquivos2.saude.gov.br/images/pdf/2020/janeiro/29/af-guia-tratamento-malaria-28jan20-isbn.pdf
11.
Brasil. Ministério da Saúde. Critérios para orientar o processo de decisão para introdução da vacina contra dengue no Programa Nacional de Imunizações (PNI) (2016). https://portalarquivos2.saude.gov.br/images/pdf/2016/maio/05/relatorio-01-criterios-orientar-decisao-vacina-dengue.pdf
12.
Domingues CMAS, Teixeira AMS. Vaccine coverage and vaccine-preventable diseases in Brazil from 1982 to 2012: advances and challenges of the National Immunization Program. Epidemiologia e Serviços de Saúde 22(1), 9–27 (2013).
13.
Pan American Health Organization. Malária (2016). https://www.paho.org/bra/index.php?option=com_content&view=article&id=5287:malaria-2&Itemid=875
•• Important reference source associated with the development of vaccines for malaria.
14.
Brasil. Ministério da Saúde. Boletim Epidemiológico (2020). https://antigo.saude.gov.br/images/pdf/2020/April/24/Boletim-epidemiologico-SVS-17-.pdf
15.
Aguiar ASC, Rocha EMM, Souza NB, França TC, Krettli AU. New approaches in antimalarial drug discovery and development. Mem. Inst. Oswaldo Cruz. 107(7), 831–845 (2012).
16.
Andrews KA, Wesche D, McCarthy J et al. Model-Informed drugs development for malaria therapeutics. Annu. Rev. Pharmacol. Toxicol. 58, 567–582 (2018).
17.
Fundação Osvaldo Cruz. Resultados de pesquisa podem ajudar no desenvolvimento de vacina contra malária. (2018). https://portal.fiocruz.br/noticia/resultados-de-pesquisa-podem-ajudar-no-desenvolvimento-de-vacina-contra-malaria
18.
Hoffman SL, Vekemans J, Richie TL et al. The march toward malaria vaccines. Am. J. Med. Ant. 49(6S4), S319–S333 (2015).
19.
Frimpong A, Kusi KA, Ofori MF, Ndifon W. Novel strategies for malaria vaccine design. Front Immunol. 9, 2769 (2018).
20.
Condessa ALC. Antimalarial vaccination: RTS, S and inactivated sporozoite vaccines from Plasmodium falciparum. Dissertation (Integrated Master in Medicine) – University of Lisbon 41 (2018).
•• Important reference source associated with the development of vaccines for malaria.
21.
Van den Berg M, Ogutu B, Sewankambo NK, Biller-Andorno N, Tanner M. RTS, S malaria vaccine pilot studies: addressing the human realities in large-scale. clinical trials. Trials 20(1), 316 (2019).
22.
Laurens MB. RTS, S/AS01 vaccine (Mosquirix). An overview. Hum. Vaccin. Immunother. 16(3), 480–489 (2020).
23.
Bell GJ, Loop MS, Mvalo T et al. Environmental modifiers of RTS, S/AS01 malaria vaccine efficacy in Lilongwe, Malawi. BMC Public Health 20(1), 910 (2020).
24.
Chandramohan D, Dicko A, Zongo I et al. Seasonal malaria vaccination: protocol of a phase 3 trial of seasonal vaccination with the RTS, S/AS01 vaccine, seasonal malaria chemoprevention and the combination of vaccination and chemoprevention. BMJ Open 10(9), e035433 (2020).
25.
Kazmin D, Nakaya HI, Lee EK et al. Systems analysis of protective immune responses to RTS, S malaria vaccination in humans. Proc. Natl Acad. Sci. USA 114(9), 2425–2430 (2017).
26.
Dobaño C, Sanz H, Sorgho H et al. Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS, S/AS01E malaria vaccine efficacy. Nat. Commun. 10(1), 2174 (2019).
27.
Collins KA, Snaith R, Cottingham MG, Gilbert SC, Hill AVS. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci. Rep. A7, 46621 (2017).
28.
Vandoolaeghe P, Schuerman L. The RTS, S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination. Expert Rev Vaccines. 15(12), 1481–1493 (2016).
29.
Santana RS, Lupatini EO, Leite SN. The regulation and adoption of health technologies under Brazil's Unified Health System: barriers to access to medicines for diseases of poverty? Ciên Saúde Coletiva 22(5), 1417–1428 (2017).
30.
Brasil. Registros de novos medicamentos: saiba o que e preciso (2020). http://portal.anvisa.gov.br/noticias/-/asset
31.
Godói IP, Santos AS, Brandão CMR et al. Consumer willingness to pay for Dengue vaccine (CYD-TDV, Dengvaxia®) in Brazil; implications for future pricing considerations. Front. Pharmacol. 8(41), 1–9 (2017).
32.
Brasil. Comissão Nacional de Incorporação de Tecnologias no Sistema Único de Saúde. A comissão (2020). http://conitec.gov.br/entenda-a-conitec-2
33.
Farias CML, Giovanella L, Oliveira AE, Santos Neto ET. Tempo de espera e absenteísmo na atenção especializada: um desafio para os sistemas universais de saúde. Saúde em Debate 43(Suppl. 5), 190–204 (2019).
34.
Muniz Júnior RL, Godói IP, Reis EA et al. Consumer willingness to pay for a hypothetical Zika vacine in Brazil and the implications. Expert Rev. Pharmacoecon. Outcomes Res. 19(4), 473–482 (2018).
35.
Brasil. Agência Nacional de Saúde Suplementar. Quem Somos (2020). http://www.ans.gov.br/aans/quem-somos
36.
Albuquerque C, Piovesan MF, Santos IS, Martin AC, Fonseca AL, Sasson D. The current situation of the private health plans and insurance Market in Brazil and trends for the future. Ciên Saúde Coletiva 13(5), 1421–1430 (2008).
37.
Brasil. Sistema Único de Saúde: estrutura, princípios, e como funciona (2020). http://www.ans.gov.br/aans/quem-somos
38.
Haab T, McConnell K. Valuing Environmental and Natural Resources: the economics of non-market valuation. New Horizons in Environmental Economics. Edward Elgar Publishing Limited, UK (2002).
•• Important to complement our knowledge of willingness to pay approach.
39.
Lee JS, Mogasale V, Lim JK, Carabali M, Sirivichayakul C. Tho le H. A multi-country study of the household willingness-to-pay for Dengue Vaccines: household surveys in Vietnam, Thailand, and Colombia. PLoS Negl. Trop. Dis. 9(6), e0003810 (2015).
40.
Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddard G. Methods for the economic evaluation of health care programmes. Oxford University Press, UK (2015).
41.
Sarmento TTR, Godói IP, Reis EA et al. Consumer willingness to pay for a hypothetical chikungunya vaccine in Brazil and the implications. Expert Rev Pharmacoecon. Outcomes Res. 19(4), 473–482 (2019).
42.
Instituto Brasileiro de Geografia e Estatística. Cidades-Panorama (2018). https://cidades.ibge.gov.br/brasil/pa/maraba/panorama
43.
Instituto Brasileiro de Geografia e Estatística. IBGE divulga o rendimento domiciliar per capita e o coeficiente de desequilíbrio regional 2019 (2019). https://agenciadenoticias.ibge.gov.br/agencia-sala-de-imprensa/2013-agencia-de-noticias/releases/27810-ibge-divulga-o-rendimento-domiciliar-per-capita-e-o-coeficiente-de-desequilibrio-regional-2019
44.
Agência Brasil. IBGE: rendimento domiciliar per capita (2019). http://agenciabrasil.ebc.com.br/renda_domiciliar_per_capita_2019.pdf
45.
Athie TS, Nascimento GC, da Costa MJL et al. Consumer willingness to pay for a hypothetical Chagas disease vaccine in Brazil: a cross-sectional study and the implications. Expert Rev Pharmacoecon. Outcomes Res. 10(8), 659–672 (2021).
•• Important to complement our knowledge of willingness to pay approach.
46.
Godói IPD, Sarmento TTR, Reis EA et al. Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer: a cross-sectional study and the implications. Expert Rev. Pharmacoecon. Outcomes Res. (2021).
47.
Brasil. Agência Nacional de Vigilância Sanitária. Resolução CMED n° 2, de 05 de março de 2004 (2004). https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/cmed/legislacao/arquivos/arquivos-resolucoes/6324json-file-1
48.
Agência Nacional de Vigilância Sanitária. Preços máximo de medicamentos por princípio Ativo (2020). https://www.gov.br/anvisa/pt-br
49.
Al-Hanaw MK, Vaidya K, Alsharqi O, Onwujekwe O. Investigating the willingness to pay for a contributory National Health Insurance Scheme in Saudi Arabia: a cross-sectional stated preference approach. Appl. Health Econ. Health Policy 16(2), 259–271 (2018).
50.
Jofre-Bonet M, Kamara J. Willingness to pay for health insurance in the informal sector of Sierra Leone. PLoS One 13(5), e0189915 (2018).
51.
Agência Nacional de Saúde Suplementar. Cadernos de Informações da Saúde Suplementar: Beneficiários, Operadoras e Planos (2019). http://www.ans.gov.br/images/stories/Materiais_para_pesquisa/Perfil_setor/Dados_e_indicadores_do_setor/total-cad-info-jun-2019.pdf
52.
Brasil. Banco Central do Brasil. Conversor de Moedas (2020). https://www.bcb.gov.br/conversao
53.
Palanca-Tan R. The demand for a dengue vaccine: a contingent valuation survey in Metro Manila. Vaccine 26(7), 914–923 (2008).
54.
Hadisoemarto PF, Castro MC. Public acceptance and willingness-to-pay for a future Dengue vaccine: a community-based survey in Bandung, Indonesia. PLoS Negl. Trop. Dis. 7(9), e2427 (2013).
55.
White SE, Harvey SA, Meza G et al. Acceptability of a herd immunity-focused, transmission-blocking malaria vaccine in malaria-endemic communities in the Peruvian Amazon: an exploratory study. Malar. J. 17(1), 179 (2018).
56.
Udezi WA, Usifoh CO, Ihimekpen OO. Willigness to pay for three hypothetical malaria vaccines in Nigeria. Clin. Ther. 32(8), 1533–1544 (2010).
57.
Harapan H, Fajar JK, Kuch U et al. Dengue vaccine acceptance and willingness to pay. Hum. Vaccine Imunother. 13(4), 786–790 (2017).
58.
IBGE. PNS 2019: sete em cada dez pessoas que procuram o mesmo serviço de saúde vão à rede pública (2020). https://agenciadenoticias.ibge.gov.br/agencia-sala-de-imprensa/2013-agencia-de-noticias/releases/28793-pns-2019-sete-em-cada-dez-pessoas-que-procuram-o-mesmo-servico-de-saude-vao-a-rede-publica
59.
Silveira RP, Pinheiro R. Understanding the need for doctors in innerstate Amazon – Brazil. Rev. Bra Edu. Med. 38(4), 451–459 (2014).
60.
Rathgeber EM, Vlassoff C. Gender and tropical diseases: a new focus. Soc. Sci. Med. 37(4), 513–520 (1993).
61.
Yasunaga H, Ide H, Imamura T, Ohe K. Willingness to pay for health services in cold detachment, common retinal, and myocardial infarction: an internet survey in Japan. BMC Health Serv. Res. 6, 12 (2006).
62.
Kim SY, Sagiraju HK, Russell LB. Willingness to pay for vaccine in low and middle-income countries: a systematic review. Ann. Vaccines Immun. 1(1), 1001 (2014).
63.
Instituto Brasileiro de Pesquisas Espaciais. A taxa consolidada de desmatamento por corte raso para os nove estados da Amazônia Legal (AC, AM, AP, MA, MT, PA, RO, RR e TO) em 2019 é de 129 km2. (2020) http://www.inpe.br/noticias/noticia.php?Cod_Noticia=5465
64.
Instituto de Pesquisa Econômica Aplicada (IPEA). A ameaça do desmatamento (2015). https://www.ipea.gov.br/desafios/index.php?option=com_content&id=3176
65.
Organização Pan-Americana da Saúde (OPAS). OMS recomenda vacina inovadora contra malária para crianças em risco (2021). https://www.paho.org/pt/noticias/6-10-2021-oms-recomenda-vacina-inovadora-contra-malaria-para-criancas-em-risco
•• Important reference source associated with the development of vaccines for malaria.
Information & Authors
Information
Published In
Pages: 263 - 274
PubMed: 35029122
Copyright
© 2022 Future Medicine Ltd.
History
Received: 18 March 2021
Accepted: 29 November 2021
Published online: 14 January 2022
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Willingness to pay for a hypothetical malaria vaccine in Brazil: a cross-sectional study and the implications. (2022) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2021-0073
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Obinna Felix Dim, Uzochukwu Emmanuel Chima, Francis Chibuike Iloabuchi, Chigozie Gloria Anene-Okeke, Chukwuemeka Augustine Nwachuya, Jennifer Chinaecherem Onyehalu, Anthony Uche Umeh, Chinonso Anne Agbo, Juliet Ekenedilichukwu Agbo, Abdulmuminu Isah, Awareness, acceptability, and willingness to pay for the R21/Matrix-M malaria vaccine: a cross-sectional study among pregnant women and nursing mothers in Enugu State, Nigeria, BMC Public Health, 10.1186/s12889-025-25405-1, 25, 1, (2025).
- Muhammad Sale Musa, Abdulwahab Kabir Sulaiman, Fatimah Isma'il Tsiga-Ahmed, Abdulaziz Tijjani Bako, Sahabi Kabir Sulaiman, Acceptance of malaria vaccine among mothers of under-five children in Nigeria: Results from the M-VAN survey, Vacunas (English Edition), 10.1016/j.vacune.2024.10.005, 25, 4, (439-447), (2024).
- Muhammad Sale Musa, Abdulwahab Kabir Sulaiman, Fatimah Isma'il Tsiga-Ahmed, Abdulaziz Tijjani Bako, Sahabi Kabir Sulaiman, Acceptance of malaria vaccine among mothers of under-five children in Nigeria: Results from the M-VAN survey, Vacunas, 10.1016/j.vacun.2024.06.007, 25, 4, (439-447), (2024).
- Vinícius Gonçalves Nogueira, Edna Afonso Reis, Brian Godman, Antony Paul Martin, Isabella Piassi Dias Godói, Acceptability and willingness to pay for a hypothetical HIV vaccine in Brazil and the implications: a cross-sectional study, Expert Review of Pharmacoeconomics & Outcomes Research, 10.1080/14737167.2024.2384543, 25, 1, (91-100), (2024).
- Omer Ben-Aharon, Ruslan Sergienko, Georgi Iskrov, Dan Greenberg, Willingness to pay for an mRNA-based anti-cancer treatment: results from a contingent valuation study in Israel, Israel Journal of Health Policy Research, 10.1186/s13584-024-00594-z, 13, 1, (2024).
- Catterina Ferreccio, How Did We Get Here: The Best Vaccines Ever Facing the Highest Public Hesitancy?, Vaccines, 10.3390/vaccines11081323, 11, 8, (1323), (2023).
- Gesiane Cavalcante Nascimento, Maria José Labis da Costa, Thannuse Silva Athie, Juliana de Sales Silva, Edna Afonso Reis, Celline Cardoso Almeida-Brasil, Brian Godman, Isabella Piassi Dias Godói, Acceptability and Consumer Willingness to pay for a hypothetical HIV vaccine in Northern Brazil: A cross-sectional study and the implications, Journal of HIV/AIDS & Social Services, 10.1080/15381501.2022.2029660, 21, 2, (145-166), (2022).